A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

Exclusion Criteria

• •Known severe allergic reactions to TCZ or other monoclonal antibodies
• •Active tuberculosis (TB) infection
• •Suspected active bacterial, fungal, viral, or other infection (besides SARS-CoV-2)
• •Participants who are on a mechanical ventilator \> 24 hours or extracorporeal membrane oxygenation (ECMO), in shock, or combination thereof with other organ failure requiring treatment in an ICU
• •In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
• •Receipt of oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months
• •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 10 x ULN detected within 24 hours at screening or at baseline (according to local laboratory reference ranges)
• •Absolute neutrophil count (ANC) \< 1000/uL at screening and baseline (according to local laboratory reference ranges)
• •Platelet count \< 50,000/uL at screening and baseline (according to local laboratory reference ranges)
• •Pregnancy or breastfeeding, or positive pregnancy test at a predose examination
• •Treatment with an investigational drug within 5 drug-elimination half-lives or 30 days (whichever is longer) of randomization